![](https://endpts.com/wp-content/uploads/2021/09/Michael-Morrissey-Exelixis-tile-scaled.jpg)
Michael Morrissey, Exelixis CEO
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Exelixis’ trial of Cabometyx and Tecentriq for patients with metastatic non-small cell lung cancer failed to meet its goal of extending overall survival compared to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.